Stock Fundamentals

Company Information

Company Name
United Therapeutics Corporation
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Exchange
NASDAQ
ISIN: US91307C1027
CIK: 0001082554
CUSIP: 91307C102
Currency: USD
Full Time Employees: 1,400
Phone: 301 608 9292
Fiscal Year End: December
IPO Date: Jun 17, 1999
Description:

United Therapeutics Corporation engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. It offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Nebulized Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients. It also markets and sells Unituxin (dinutuximab) injection, a monoclonal antibody for high-risk neuroblastoma; and Remunity Pump, which contains a pump and separate controller for Remodulin. In addition, it is involved in developing RemunityPRO Pump and Ralinepag for the treatment of PAH;and Nebulized Tyvaso, for the treatment of idiopathic pulmonary fibrosis, as well as xenografts, which are development-stage organ products. Further, it provides preclinical products, including EVLP/CLES, for lung transplant; UKidney, UHeart, UThymoKidney, a development-stage gene-edited porcine kidneys and hearts for xenotransplantation; ULobe, for allogeneic regenerative medicine; ULung, for autologous regenerative medicine; IVIVA Kidney, for autologous regenerative medicine; miroliver, for allogeneic regenerative medicine; and mirokidney, for allogeneic regenerative medicine. It has licensing and collaboration agreements with DEKA Research & Development Corp. to develop a semi-disposable system for the subcutaneous delivery of treprostinil; MannKind Corporation to develop and license treprostinil inhalation powder and the Dreamboat device; and Arena Pharmaceuticals, Inc. to develop Ralinepag. The company was founded in 1996 and is headquartered in Silver Spring, Maryland.

Address:

1000 Spring Street, Silver Spring, MD, United States, 20910

Directors & Officers

Name Title Year Born
Dr. Martine A. Rothblatt J.D., M.B.A., Ph.D. Founder, Chairman & CEO 1955
Mr. Michael I. Benkowitz President & COO 1972
Mr. James C. Edgemond CFO & Treasurer 1968
Mr. Paul A. Mahon J.D. Executive VP, General Counsel & Corporate Secretary 1964
Harrison Silvers Manager of Investor Relations NA
Ms. Holly Hobson Associate Vice President of Human Resources NA
Dr. Leigh Peterson Executive Vice President of Product Development & Xenotransplantation NA
Mr. Gil Golden Senior VP & Chief Medical Officer NA

Insider Trading

Date Insider Name Title Transaction Type Shares Price Value
Apr 24, 2026 Christopher Patusky N/A Sale 2.91K $569.00 $1.66M
Apr 23, 2026 James Edgemond N/A Sale 9.64K $572.21 $5.51M
Apr 22, 2026 James Edgemond N/A Sale 364.00 $575.85 $209.61K
Apr 22, 2026 Martine A Rothblatt N/A Sale 9.50K $576.56 $5.48M
Apr 20, 2026 James Edgemond N/A Sale 10.00K $577.86 $5.78M
Apr 20, 2026 Martine A Rothblatt N/A Sale 9.50K $577.83 $5.49M
Apr 17, 2026 Christopher Patusky N/A Sale 1.00K $578.88 $578.88K
Apr 17, 2026 Martine A Rothblatt N/A Sale 9.50K $586.66 $5.57M
Apr 16, 2026 James Edgemond N/A Sale 10.00K $577.18 $5.77M
Apr 16, 2026 Paul A Mahon N/A Sale 8.30K $576.82 $4.79M
Apr 15, 2026 Martine A Rothblatt N/A Sale 9.50K $580.36 $5.51M
Apr 13, 2026 James Edgemond N/A Sale 10.00K $574.88 $5.75M
Apr 13, 2026 Martine A Rothblatt N/A Sale 9.50K $574.86 $5.46M
Apr 10, 2026 Martine A Rothblatt N/A Sale 9.50K $569.28 $5.41M
Apr 09, 2026 James Edgemond N/A Sale 10.00K $577.89 $5.78M
Apr 08, 2026 Martine A Rothblatt N/A Sale 9.50K $580.45 $5.51M
Apr 06, 2026 James Edgemond N/A Sale 10.00K $558.40 $5.58M
Apr 06, 2026 Martine A Rothblatt N/A Sale 9.50K $558.41 $5.30M
Apr 02, 2026 James Edgemond N/A Sale 10.00K $561.50 $5.62M
Apr 02, 2026 Paul A Mahon N/A Sale 8.30K $565.87 $4.70M

Institutional Holders

Holder Name Shares Date Reported % Out Value % Change
BlackRock Inc 5.40M Mar 31, 2026 12.72% $0.06 4.43%
Vanguard Group Inc 4.18M Dec 31, 2025 9.84% $0.03 -5.49%
venBio Select Advisor LLC 2.63M Mar 31, 2026 6.20% $15.34 0.92%
Wellington Management Company LLP 2.26M Mar 31, 2026 5.33% $0.25 -7.26%
State Street Corp 1.84M Mar 31, 2026 4.34% $0.04 0.08%
Renaissance Technologies Corp 1.79M Mar 31, 2026 4.21% $1.66 -6.40%
Geode Capital Management, LLC 1.23M Mar 31, 2026 2.90% $0.05 3.35%
HHG PLC 866.93K Mar 31, 2026 2.04% $0.25 8.90%
AQR Capital Management LLC 826.23K Mar 31, 2026 1.95% $0.22 -35.54%
Genworth Financial Wealth Mgmt Inc 616.05K Mar 31, 2026 1.45% $0.74 -2.98%
Amvescap Plc. 608.37K Mar 31, 2026 1.43% $0.06 -0.06%
NORGES BANK 602.19K Dec 31, 2025 1.42% $0.03 26.81%
FMR Inc 528.35K Mar 31, 2026 1.24% $0.02 30.83%
Dimensional Fund Advisors, Inc. 512.74K Mar 31, 2026 1.21% $0.06 -2.93%
Deerfield Management Co 457.00K Mar 31, 2026 1.08% $3.20 7.28%
Northern Trust Corp 436.57K Mar 31, 2026 1.03% $0.03 4.34%
Baillie Gifford & Co Limited. 428.13K Mar 31, 2026 1.01% $0.26 32.54%
Morgan Stanley - Brokerage Accounts 409.29K Mar 31, 2026 0.96% $0.01 5.14%
T. Rowe Price Associates, Inc. 405.45K Mar 31, 2026 0.96% $0.03 15.16%
LSV Asset Management 398.67K Mar 31, 2026 0.94% $0.51 -2.30%

Shares Statistics

Shares Outstanding: 42.45M
Shares Float: 38.92M
% Insiders: 203.70%
% Institutions: 10,207.80%
Short % Float: 6.35%

Fund Holdings

Rank Holder Name Shares Held % of Shares Change Date Reported
1 iShares Core S&P Mid-Cap ETF 1.45M 3.43% ▼ 0.05% Apr 30, 2026
2 Vanguard Total Stock Mkt Idx Inv 1.40M 3.29% ▲ 0.24% Apr 30, 2026
3 Vanguard Small Cap Index 1.01M 2.38% ▼ 0.21% Apr 30, 2026
4 Vanguard Health Care Inv 855.74K 2.02% ▼ 12.21% Mar 31, 2026
5 Vanguard Small Cap Value Index Inv 648.46K 1.53% ▲ 0.70% Apr 30, 2026
6 Vanguard Institutional Extnd Mkt Idx Tr 486.09K 1.15% ▲ 1.00% Apr 30, 2026
7 Invesco S&P MidCap Quality ETF 361.15K 0.85% ▲ 0.00% Apr 30, 2026
8 State Street® SPDR® S&P MIDCAP 400® ETF 325.75K 0.77% ▲ 0.38% Apr 30, 2026
9 iShares Biotechnology ETF 313.66K 0.74% ▲ 1.42% Apr 30, 2026
10 Baillie Gifford US Equity Growth 304.13K 0.72% ▲ 63.33% Mar 31, 2026

Valuation Metrics

Enterprise Value: $20.01B
Trailing P/E: 20.31
Forward P/E: 19.88

Financial Highlights

Market Cap: $23.32B
EBITDA: $1.55B
P/E Ratio: $20.31
PEG Ratio: $2.23
Book Value: $139.98
Earnings/Share: $27.05
Profit Margin: 40.62%
Operating Margin: 41.69%
ROA (TTM): 12.62%
ROE (TTM): 20.26%
Revenue (TTM): $3.17B
Revenue/Share (TTM): $72.12
Earnings Growth (YOY): -12.20%
Revenue Growth (YOY): -1.60%

Stock Price History

1 Year Price History

2 Years Price History

5 Years Price History

10 Years Price History

Financial Charts

Revenue & Net Income (Yearly)

Revenue & Net Income (Quarterly)

Operating Expenses (Yearly)

Operating Expenses (Quarterly)

Balance Sheet (Yearly)

Balance Sheet (Quarterly)

Assets Breakdown (Yearly)

Assets Breakdown (Quarterly)

Liabilities Breakdown (Yearly)

Liabilities Breakdown (Quarterly)

Earnings Per Share (EPS) History

Financial Ratios

Balance Sheet (Yearly)

Financial Ratios

Date Current Ratio Debt/Equity Debt/Assets Interest Coverage Debt/EBITDA
2025-12-31 6.60x 0.00x 0.10x 77.81x 0.00x
2024-12-31 5.25x 0.05x 0.12x 32.10x 0.18x
2023-12-31 4.41x 0.12x 0.16x 19.98x 0.50x
2022-12-31 9.85x 0.17x 0.21x 30.24x 0.77x
2021-12-31 7.61x 0.20x 0.23x 29.89x 1.09x
2020-12-31 6.70x 0.24x 0.26x 25.26x 1.24x
2019-12-31 4.03x 0.31x 0.29x -4.24x -11.35x
2018-12-31 6.39x 0.09x 0.18x 57.94x 0.30x
2017-12-31 3.26x 0.24x 0.27x 90.54x 0.47x
2016-12-31 4.29x 0.00x 0.20x 272.23x 0.00x
2015-12-31 2.89x 0.00x 0.27x 147.63x 0.00x
2014-12-31 1.93x 0.10x 0.33x 30.63x 0.22x
2013-12-31 1.32x 0.22x 0.38x 16.20x 0.88x
2012-12-31 3.78x 0.25x 0.33x 25.34x 0.57x
2011-12-31 2.65x 0.28x 0.38x 14.87x 0.78x
2010-12-31 1.78x 0.34x 0.38x 8.32x 1.64x
2009-12-31 0.98x 0.38x 0.38x 2.02x 5.82x
2008-12-31 5.14x 0.55x 0.42x -5,128.50x -4.12x
2007-12-31 1.29x 0.85x 0.50x 2.90x 11.27x
2006-12-31 14.41x 1.22x 0.57x 60.13x 8.63x
2005-12-31 11.48x 0.00x 0.06x 1,479.07x 0.00x
2004-12-31 7.97x 0.00x 0.07x 3,302.25x 0.00x
2003-12-31 8.45x 0.00x 0.07x -102.91x -0.09x
2002-12-31 15.24x 0.01x 0.07x -153.87x -0.13x
2001-12-31 6.39x 0.01x 0.07x -271.77x -0.04x
2000-12-31 19.33x 0.01x 0.06x -678.97x -0.02x
1999-12-31 11.46x 0.00x 0.11x N/A 0.00x
1998-12-31 9.33x 0.00x 0.11x N/A 0.00x

📦 Raw API Data (JSON Explorer)

Watchlist

0

No stocks in watchlist

Assistant

×
Hello! I'm your AI assistant. I have access to the financial data on this page. Ask me anything about UTHR.US!